{"publication_id":"1a265041-dcba-4d47-9a2a-af0e73104267","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Clinical experience with the <scp>BCL</scp>2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies","doi":"10.1002/ajh.25000","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL","doi":"10.1200/jco.23.01075","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients","doi":"10.1002/ajh.25978","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","doi":"10.1182/blood-2018-08-868752","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Phase I/II Study of the All-Oral Combination of Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML","doi":"10.1182/blood-2024-204375","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Exploring the effects of Dasatinib, Quercetin, and Fisetin on DNA methylation clocks: a longitudinal study on senolytic interventions","doi":"10.18632/aging.205581","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}